WallStreetZenWallStreetZen

NASDAQ: LHDX
Lucira Health Inc Stock Forecast, Predictions & Price Target

Analyst price target for LHDX

Based on 2 analysts offering 12 month price targets for Lucira Health Inc.
Min Forecast
$3.00+782.35%
Avg Forecast
$3.50+929.41%
Max Forecast
$4.00+1,076.47%

Should I buy or sell LHDX stock?

Based on 3 analysts offering ratings for Lucira Health Inc.
Hold
Strong Buy
1 analysts 33.33%
Buy
0 analysts 0%
Hold
1 analysts 33.33%
Sell
1 analysts 33.33%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their LHDX stock forecasts and price targets.

Forecast return on equity

Is LHDX forecast to generate an efficient return?
Company
138.69%
Industry
63.77%
Market
57.54%
LHDX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is LHDX forecast to generate an efficient return on assets?
Company
44.64%
Industry
14.75%
LHDX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

LHDX earnings per share forecast

What is LHDX's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$1.09
Avg 2 year Forecast
$1.49
Avg 3 year Forecast
$2.08

LHDX revenue forecast

What is LHDX's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$284.9M+34.31%
Avg 2 year Forecast
$574.9M+171.03%
Avg 3 year Forecast
$708.3M+233.9%
LHDX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

LHDX revenue growth forecast

How is LHDX forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
56.98%
Industry
11.72%
Market
11.02%
LHDX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
LHDX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

LHDX vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
LHDX$0.34$3.50+929.41%Hold
NDRA$4.12$5.00+21.36%Buy
ONVO$1.68N/AN/A
ISPC$1.68$4.25+152.98%Strong Buy
CEMI$0.44N/AN/AHold

Lucira Health Stock Forecast FAQ

Is Lucira Health Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: LHDX) stock is to Hold LHDX stock.

Out of 3 analysts, 1 (33.33%) are recommending LHDX as a Strong Buy, 0 (0%) are recommending LHDX as a Buy, 1 (33.33%) are recommending LHDX as a Hold, 1 (33.33%) are recommending LHDX as a Sell, and 0 (0%) are recommending LHDX as a Strong Sell.

If you're new to stock investing, here's how to buy Lucira Health stock.

What is LHDX's earnings growth forecast for 2023-2025?

(NASDAQ: LHDX) Lucira Health's forecast annual earnings growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 34.91%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 27.25%.

Lucira Health's earnings in 2023 is -$143,276,000.On average, 2 Wall Street analysts forecast LHDX's earnings for 2023 to be -$44,252,860, with the lowest LHDX earnings forecast at -$72,672,128, and the highest LHDX earnings forecast at -$15,833,592. On average, 2 Wall Street analysts forecast LHDX's earnings for 2024 to be $60,289,447, with the lowest LHDX earnings forecast at $45,470,828, and the highest LHDX earnings forecast at $75,108,065.

In 2025, LHDX is forecast to generate $84,445,824 in earnings, with the lowest earnings forecast at $51,966,661 and the highest earnings forecast at $116,924,988.

What is LHDX's revenue growth forecast for 2023-2025?

(NASDAQ: LHDX) Lucira Health's forecast annual revenue growth rate of 56.98% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 11.72%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 11.02%.

Lucira Health's revenue in 2023 is $212,134,000.On average, 2 Wall Street analysts forecast LHDX's revenue for 2023 to be $11,567,453,974, with the lowest LHDX revenue forecast at $8,931,769,880, and the highest LHDX revenue forecast at $14,203,138,067. On average, 2 Wall Street analysts forecast LHDX's revenue for 2024 to be $23,342,165,608, with the lowest LHDX revenue forecast at $22,177,178,623, and the highest LHDX revenue forecast at $24,507,152,593.

In 2025, LHDX is forecast to generate $28,756,645,108 in revenue, with the lowest revenue forecast at $24,359,372,400 and the highest revenue forecast at $33,153,917,815.

What is LHDX's forecast return on assets (ROA) for 2023-2025?

(NASDAQ: LHDX) forecast ROA is 44.64%, which is higher than the forecast US Diagnostics & Research industry average of 14.75%.

What is LHDX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year LHDX price target, the average LHDX price target is $3.50, with the highest LHDX stock price forecast at $4.00 and the lowest LHDX stock price forecast at $3.00.

On average, Wall Street analysts predict that Lucira Health's share price could reach $3.50 by Aug 15, 2023. The average Lucira Health stock price prediction forecasts a potential upside of 929.41% from the current LHDX share price of $0.34.

What is LHDX's Earnings Per Share (EPS) forecast for 2023-2025?

(NASDAQ: LHDX) Lucira Health's current Earnings Per Share (EPS) is -$3.51. On average, analysts forecast that LHDX's EPS will be -$1.09 for 2023, with the lowest EPS forecast at -$1.79, and the highest EPS forecast at -$0.39. On average, analysts forecast that LHDX's EPS will be $1.49 for 2024, with the lowest EPS forecast at $1.12, and the highest EPS forecast at $1.85. In 2025, LHDX's EPS is forecast to hit $2.08 (min: $1.28, max: $2.88).

What is LHDX's forecast return on equity (ROE) for 2023-2025?

(NASDAQ: LHDX) forecast ROE is 138.69%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.